Effect of polyphloretin-phosphate, an inhibitor of prostaglandins, on the spontaneous and induced motility of isolated rat uterus.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to F Lima.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
OBJECTIVE: To study the maternal and fetal outcome in treated antiphospholipid syndrome (APS) pregnancies. METHODS: Sixty pregnancies in 47 APS patients (11 primary and 36 secondary) were followed in a multidisciplinary clinic. Patients testing antiphospholipid antibody positive and having a history of recurrent miscarriages were treated with low-dose aspirin (75 mg) daily. Patients with APS and a previous history of thrombotic events were treated with subcutaneous unfractionated or low molecular weight heparin and low-dose aspirin (75 mg) daily. RESULTS: The live birth rate increased from 19% of their previous non-treated pregnancies to 70% despite a high incidence of obstetric and fetal complications: pre-eclampsia (18%), prematurity (43%), fetal distress (50%) and intrauterine growth retardation (31%). Two predictors of fetal outcome were observed: the previous obstetric history and the presence of thrombocytopenia. Seven pregnancies (12%) were complicated by thrombotic events during pregnancy or during the puerperium. There were no thrombotic events in those receiving a low molecular weight heparin regimen. CONCLUSION: Close obstetric monitoring by a multidisciplinary team and the use of antithrombotic therapy was effective in reducing the fetal wastage in APS pregnancies despite a high incidence of obstetric and fetal complications.
Male osteoporosis is increasingly recognized as an important public health issue. Possible factors include alcohol and tobacco consume and longer life expectancy. The main causes of male osteoporosis are secondary, as hypogonadism, use of glucorticoids and other drugs. The age-related decline in testosterone may be concomitant of ageing or may contribute to reduced bone formation and bone loss in men. Currently, therapy decisions are based on studies in women and animal models, once there is no trials with definitive results in men. Therefore, the aim of this review is to analyse some features of pathophysiology of bone loss in men, as well as the aetiological factors, clinical characteristics and therapy.